Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC5A2 | P31639 | 20/20 | 1.00 |
| ▸ | SLC5A1 | P13866 | 13/20 | 1.00 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.70 |
| ▸ | SLC5A11 | Q8WWX8 | 1/20 | 0.70 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL302062 | 1.00 | SLC5A2 (1.00) | SLC5A2SLC5A1ADRA2ASLC5A11 | |
| SCHEMBL500488 | 1.00 | SLC5A2 (1.00) | SLC5A2SLC5A1ADRA2ASLC5A11 | |
| SCHEMBL14324871 | 1.00 | SLC5A2 (1.00) | SLC5A2SLC5A1ADRA2ASLC5A11 | |
| SCHEMBL24105577 | 0.92 | SLC5A2 (0.86) | SLC5A2SLC5A1ADRA2ASLC5A11 | |
| SCHEMBL20124638 | 0.90 | SLC5A2 (0.81) | SLC5A2SLC5A1ADRA2ASLC5A11 | |
| SCHEMBL499848 | 0.90 | SLC5A2 (0.81) | SLC5A2SLC5A1ADRA2ASLC5A11 | |
| SCHEMBL499901 | 0.90 | SLC5A2 (0.81) | SLC5A2SLC5A1ADRA2ASLC5A11 | |
| SCHEMBL27368116 | 0.88 | SLC5A2 (0.90) | SLC5A2SLC5A1ADRA2ASLC5A11 | |
| SCHEMBL19494518 | 0.87 | SLC5A2 (0.79) | SLC5A2SLC5A1ADRA2ASLC5A11 | |
| SCHEMBL14324857 | 0.87 | SLC5A2 (0.79) | SLC5A2SLC5A1ADRA2ASLC5A11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2187742-B1 | (2S,3R,4R,5S,6R)-2-(4-CHLORO-3-BENZYLPHENYL)-6-(HYDROXYMETHYL)TETRAHYDRO-2H-PYRAN-3,4,5-TRIOL DERIVATIVES FOR USE IN THE TREATMENT OF DIABETES | THERACOS SUB LLC (US) | 2017-10-25 | — | — | EP | disclosed |